

Valeo Pharma to Host First Quarter 2022 Results Conference Call / Webcast and Attend the 8th Annual AlphaNorth Capital Conference

written by Raj Shah | March 17, 2022

March 17, 2022 ([Source](#)) – [Valeo Pharma Inc.](#) (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“**Valeo**” or the “**Company**”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2022 on Thursday March 24, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Friday March 25, 2022 at 8.30am (ET).

Conference ID:	79726898
Date:	Friday, March 25, 2022
Time:	8:30am ET
Dial-in numbers:	1-888-664-6392 or 416-764-8659
Audio replay numbers:	1-888-390-0541 or 416-764-8677
Replay code:	726898#

A live audio webcast of the conference call will be available via: https://produceredition.webcasts.com/starthere.jsp?ei=1536136&tp_key=d562d32471

AlphaNorth 8th Annual Conference

The Company also announces that it will attend the 8th annual

AlphaNorth Capital Investment Conference in Nassau, Bahamas on March 25-27, 2022.

The annual [AlphaNorth Capital Conference](#) provides an opportunity for fast growing companies like Valeo to meet with investors and present its investment opportunities through a day of scheduled in person one-on-one meetings. Participants on the investor side include top brokers, portfolio managers, institutional investors and high net worth individual investors active in growth stocks and looking for new opportunities for themselves and their clients.

To arrange a one-on-one meeting with the Company at the event, please contact Valeo's investor relations department at dumais@valeopharma.com.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on [LinkedIn](#) and [Twitter](#).

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions.

Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Valeo Pharma Inc. 

For further information: Steve Saviuk, CEO, 514-693-8830, saviuk@valeopharma.com or Luc Mainville, Senior Vice-President and Chief Financial Officer, 514-693-8854, mainville@valeopharma.com or Frederic Dumais, Director, Communications and Investor Relations, 514-782-8803, dumais@valeopharma.com